ABEO Abeona Therapeutics Inc. Stock Quote

ABEO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	2.40%	Shs Outstand	96.51M	Perf Week	-4.62%
Market Cap	126.50M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	-6.88%	Shs Float	85.54M	Perf Month	5.98%
Income	-54.30M	PEG	-	EPS next Q	-0.16	Inst Own	28.40%	Short Float	4.39%	Perf Quarter	-27.49%
Sales	10.00M	P/S	12.65	EPS this Y	40.00%	Inst Trans	-10.47%	Short Ratio	3.53	Perf Half Y	-42.06%
Book/sh	0.87	P/B	1.43	EPS next Y	6.30%	ROA	-37.30%	Target Price	-	Perf Year	-34.39%
Cash/sh	0.76	P/C	1.63	EPS next 5Y	-	ROE	-54.80%	52W Range	0.99 - 3.79	Perf YTD	-21.02%
Dividend	-	P/FCF	-	EPS past 5Y	-11.50%	ROI	-78.10%	52W High	-67.28%	Beta	1.48
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	57.30%	Gross Margin	-	52W Low	25.32%	ATR	0.07
Employees	76	Current Ratio	1.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.56	Volatility	4.87% 5.48%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-12.90%	Profit Margin	-	Rel Volume	0.35	Prev Close	1.24
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 28 AMC	Payout	-	Avg Volume	1.06M	Price	1.24
Recom	1.70	SMA20	-2.63%	SMA50	-3.70%	SMA200	-27.59%	Volume	371,539	Change	0.00%

Nov-11-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

Sep-18-20

Initiated

B. Riley FBR

Buy

Feb-10-20

Initiated

SVB Leerink

Outperform

Dec-10-19

Resumed

Cantor Fitzgerald

Neutral

$2 → $4

Aug-15-19

Downgrade

Maxim Group

Buy → Hold

Aug-12-19

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$29 → $2

Jul-26-19

Downgrade

Mizuho

Buy → Neutral

$17 → $4

Jun-27-19

Initiated

Mizuho

Buy

Oct-12-18

Initiated

Mizuho

Buy

$17

Jun-05-18

Initiated

Seaport Global Securities

Buy

$29

Nov-08-17

Initiated

SunTrust

Buy

$26

Oct-16-17

Reiterated

H.C. Wainwright

Buy

$20 → $30

Oct-11-17

Reiterated

Cantor Fitzgerald

Overweight

$21 → $34

Oct-10-17

Initiated

Citigroup

Buy

$32

Oct-05-17

Reiterated

Maxim Group

Buy

$17 → $35

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$23

Jul-18-17

Reiterated

Maxim Group

Buy

$14 → $17

Jun-22-17

Resumed

Jefferies

Buy

$22

Jan-06-17

Initiated

Jefferies

Buy

Sep-29-16

Reiterated

Maxim Group

Buy

$8 → $14

Sep-07-21 07:30AM	Abeona Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-10-21 07:30AM	Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer GlobeNewswire
Jul-28-21 04:01PM	Abeona Therapeutics Reports Second Quarter Financial Results GlobeNewswire
07:30AM	Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) GlobeNewswire
Jul-26-21 07:30AM	Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy GlobeNewswire
06:12AM	Abeona Reports Positive Data for Sanfilippo Syndrome Treatment TheStreet.com
Jul-23-21 07:30AM	Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL Study for Recessive Dystrophic Epidermolysis Bullosa GlobeNewswire
Jul-07-21 12:02PM	Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder Benzinga
07:30AM	Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting GlobeNewswire
Jun-14-21 10:00AM	10 Penny Stocks Robinhood Traders are Buying in 2021 Insider Monkey
Jun-02-21 07:30AM	Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-26-21 07:30AM	Abeona Therapeutics Issues Letter to Stockholders GlobeNewswire +10.74%
May-25-21 07:30AM	Abeona Therapeutics Appoints Head of Research & Clinical Development GlobeNewswire
06:45AM	Abeona Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-18-21 07:30AM	Abeona Therapeutics Reports First Quarter Financial Results GlobeNewswire +14.71%
May-11-21 06:06AM	Moving Average Crossover Alert: Abeona Therapeutics (ABEO) Zacks
Apr-20-21 07:30AM	Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting GlobeNewswire
Apr-19-21 07:30AM	Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors GlobeNewswire -5.37%
Mar-25-21 07:30AM	Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors GlobeNewswire +5.62%
Mar-24-21 05:15PM	Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue Estimates Zacks -6.32%
04:01PM	Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress GlobeNewswire
Mar-23-21 12:41PM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire -6.86%
Mar-22-21 07:30AM	Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer GlobeNewswire -6.42%
Mar-11-21 11:22PM	Abeona Therapeutics' (NASDAQ:ABEO) Shareholders Are Down 85% On Their Shares Simply Wall St.
Feb-25-21 11:33AM	Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks TipRanks +13.18%
Feb-22-21 07:30AM	Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -7.47%
Feb-12-21 11:36AM	New Positive Phase 1/2 Interim Data Presented at WORLDSymposium Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeonas ABO-102 Gene Therapy GlobeNewswire -11.90%
Feb-02-21 07:30AM	Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium GlobeNewswire
Jan-25-21 07:30AM	Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) GlobeNewswire +9.91%
Jan-12-21 08:50AM	Do Options Traders Know Something About Abeona (ABEO) Stock We Don't? Zacks
Dec-21-20 12:20PM	Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium GlobeNewswire
Dec-14-20 09:44PM	Is ABEO A Good Stock To Buy Now? Insider Monkey
Dec-01-20 10:06AM	Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer Zacks -6.17%
09:09AM	Is the Options Market Predicting a Spike in Abeona (ABEO) Stock? Zacks
Nov-27-20 08:25AM	HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts Zacks +17.02%
Nov-24-20 03:10PM	Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases Zacks
03:08PM	Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology Zacks
03:07PM	Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate Zacks
Nov-18-20 11:24AM	Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint Zacks +9.38%
Nov-17-20 01:16PM	Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study Zacks
Nov-12-20 05:21AM	How Much Are Abeona Therapeutics Inc. (NASDAQ:ABEO) Insiders Spending On Buying Shares? Simply Wall St. -6.92%
Nov-09-20 05:55PM	Abeona Therapeutics (ABEO) Reports Q3 Loss Zacks
04:05PM	Abeona Therapeutics Reports Third Quarter Financial Results GlobeNewswire
Oct-27-20 06:30AM	Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer GlobeNewswire -6.35%
Oct-14-20 10:58PM	Abeona Therapeutics Inc (ABEO): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Oct-06-20 04:01PM	Abeona Therapeutics Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan GlobeNewswire +11.93%
Sep-28-20 09:27AM	Abeona Therapeutics Announces Leadership and Board Transitions GlobeNewswire -41.40%
Sep-18-20 11:08AM	Why Abeona Therapeutics Is Trading Higher Today Benzinga +6.12%
09:31AM	Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga
Sep-08-20 04:05PM	Abeona Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-01-20 06:29AM	Are Institutions Heavily Invested In Abeona Therapeutics Inc.'s (NASDAQ:ABEO) Shares? Simply Wall St.
Aug-17-20 07:00AM	Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease GlobeNewswire
Aug-10-20 04:01PM	Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates GlobeNewswire
Aug-04-20 11:36AM	Did Hedge Funds Make The Right Call On Abeona Therapeutics Inc (ABEO) ? Insider Monkey
Jul-10-20 07:30AM	Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting GlobeNewswire -10.15%
Jul-09-20 09:10AM	Abeona Restarts Enrollment in Connective Tissue Disorder Study Zacks
07:30AM	Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer GlobeNewswire
Jul-08-20 07:30AM	Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies GlobeNewswire
Jul-03-20 07:48AM	Here's Why We're Watching Abeona Therapeutics's (NASDAQ:ABEO) Cash Burn Situation Simply Wall St.
Jun-23-20 11:59AM	Hedge Funds Still Crazy About Abeona Therapeutics Inc (ABEO)? Insider Monkey
Jun-18-20 07:30AM	Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting GlobeNewswire
Jun-17-20 07:30AM	Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors GlobeNewswire
Jun-08-20 09:11AM	Edited Transcript of ABEO earnings conference call or presentation 7-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-28-20 11:30AM	Is Abeona Therapeutics (ABEO) Outperforming Other Medical Stocks This Year? Zacks
08:30AM	Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference GlobeNewswire
May-08-20 12:58PM	Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y Zacks +15.45%
May-07-20 01:59PM	Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates Zacks
May-06-20 04:14PM	Abeona Therapeutics Reports First Quarter Financial Results and Business Updates GlobeNewswire
Apr-29-20 11:08AM	Moving Average Crossover Alert: Abeona Therapeutics Zacks
Apr-21-20 04:04PM	Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.58%
08:00AM	Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors GlobeNewswire
Apr-20-20 08:43AM	Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options Zacks +7.73%
06:06AM	Investors Who Bought Abeona Therapeutics (NASDAQ:ABEO) Shares A Year Ago Are Now Down 71% Simply Wall St.
Apr-17-20 07:00AM	INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Abeona Therapeutics Inc. for Potential Breach of Fiduciary Duty Claims GlobeNewswire
Apr-06-20 09:16AM	Is Abeona Therapeutics (ABEO) Stock a Solid Choice Right Now? Zacks +9.57%
Apr-05-20 04:12AM	Edited Transcript of ABEO earnings conference call or presentation 17-Mar-20 2:00pm GMT Thomson Reuters StreetEvents
Mar-27-20 06:19PM	Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic GlobeNewswire
Mar-23-20 12:00PM	Abeona Therapeutics (ABEO) Moves to Buy: Rationale Behind the Upgrade Zacks -8.45%
Mar-17-20 07:30AM	Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa GlobeNewswire +40.69%
Mar-16-20 04:20PM	Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates GlobeNewswire -16.67%
Feb-26-20 08:00AM	Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -5.14%
Feb-21-20 08:45AM	Is the Options Market Predicting a Spike in Abeona (ABEO) Stock? Zacks
Feb-12-20 02:15PM	Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium GlobeNewswire
Jan-21-20 08:00AM	Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa GlobeNewswire +9.45%
Jan-15-20 09:33AM	Abeona Therapeutics Announces Issuance of U.S. Patent for AIM Capsids GlobeNewswire
Jan-13-20 09:00AM	Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa GlobeNewswire -7.09%
Jan-02-20 12:12PM	THURSDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
11:55AM	FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm ACCESSWIRE
10:28AM	DEADLINE ALERT - Abeona Therapeutics Inc. (ABEO) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: January 2, 2019 ACCESSWIRE
04:52AM	Insider Buying: The Abeona Therapeutics Inc. (NASDAQ:ABEO) Just Bought US$500k Worth Of Shares Simply Wall St.
Dec-31-19 12:30PM	THURSDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm ACCESSWIRE -6.30%
12:00PM	ABEONA EQUITY LOSS ALERT: ROSEN, A LEADING LAW FIRM, Reminds Abeona Therapeutics Inc. Investors of Important Thursday Deadline in Securities Class Action - ABEO GlobeNewswire
Dec-27-19 08:30PM	6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm ACCESSWIRE -5.14%
06:00PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Abeona Therapeutics, Inc. and Encourages Investors to Contact the Firm Business Wire
Dec-24-19 02:20PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm ACCESSWIRE
01:30PM	ROSEN, A TOP RANKED LAW FIRM, Reminds Abeona Therapeutics Inc. Investors of Important Deadline in Securities Class Action ABEO GlobeNewswire
01:01PM	Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-20-19 06:20PM	FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm ACCESSWIRE -37.70%
10:44AM	Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA GlobeNewswire
10:22AM	Are Options Traders Betting On A Big Move In Abeona Therapeutics (ABEO) Stock? Zacks

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CARR EDWARD	Chief Accounting Officer	Apr 05	Sale	1.80	35,000	62,846	191,291	Apr 05 06:31 PM
CARR EDWARD	Chief Accounting Officer	Apr 01	Sale	1.85	20,445	37,866	226,291	Apr 05 06:31 PM
Amoroso Michael	Chief Executive Officer	Mar 31	Sale	1.87	45,409	84,919	650,046	Apr 02 07:12 PM
SCO CAPITAL PARTNERS LLC	Director	Mar 18	Sale	2.23	80,000	178,624	11,159,292	Mar 19 04:05 PM
Mann Paul Elliot	Director	Feb 19	Option Exercise	1.28	45,566	58,324	45,566	Feb 23 04:14 PM
Mann Paul Elliot	Director	Feb 19	Sale	2.38	45,566	108,502	0	Feb 23 04:14 PM
Wider Todd	Director	Feb 19	Sale	2.39	251,625	601,057	25,000	Feb 23 04:05 PM
Wider Todd	Director	Feb 18	Option Exercise	1.28	1,345	1,722	277,970	Feb 19 04:05 PM
Wider Todd	Director	Feb 18	Sale	2.43	1,345	3,273	276,625	Feb 19 04:05 PM
Wider Todd	Director	Feb 17	Option Exercise	1.28	320,000	409,600	596,625	Feb 19 04:05 PM
Mann Paul Elliot	Director	Feb 17	Sale	2.34	132,664	310,168	0	Feb 19 04:05 PM
Wider Todd	Director	Feb 17	Sale	2.34	320,000	749,792	276,625	Feb 19 04:05 PM
SCO CAPITAL PARTNERS LLC	Director	Feb 16	Sale	2.97	120,000	356,808	11,239,292	Feb 18 04:05 PM
SCO CAPITAL PARTNERS LLC	Director	Feb 08	Sale	3.01	240,000	722,832	11,359,292	Feb 10 07:42 PM
SCO CAPITAL PARTNERS LLC	Director	Jan 19	Sale	2.08	207,117	431,218	11,599,292	Jan 19 06:48 PM
SCO CAPITAL PARTNERS LLC	Director	Jan 15	Sale	2.02	81,283	164,086	11,806,409	Jan 19 06:48 PM
SCO CAPITAL PARTNERS LLC	Director	Jan 14	Sale	2.00	31,600	63,213	11,887,692	Jan 19 06:48 PM
Wider Todd	Director	Jan 04	Sale	1.54	33,876	52,064	276,625	Jan 05 07:09 PM
Mann Paul Elliot	Director	Jan 04	Sale	1.54	30,488	46,891	132,664	Jan 05 07:07 PM
Mann Paul Elliot	Director	Dec 18	Sale	1.59	17,079	27,099	772,907	Dec 21 06:16 PM
Wider Todd	Director	Dec 02	Sale	1.49	33,876	50,546	920,256	Dec 02 04:26 PM
Mann Paul Elliot	Director	Dec 02	Sale	1.49	30,488	45,369	789,986	Dec 02 04:25 PM
Wider Todd	Director	Nov 23	Sale	1.33	17,969	23,981	954,132	Nov 24 06:46 PM
Mann Paul Elliot	Director	Nov 02	Sale	1.04	30,488	31,589	820,474	Nov 06 04:54 PM
Wider Todd	Director	Nov 02	Sale	1.04	33,876	35,106	972,101	Nov 06 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience